<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Epigenetics</journal-id><journal-id journal-id-type="iso-abbrev">Clin Epigenetics</journal-id><journal-title-group><journal-title>Clinical Epigenetics</journal-title></journal-title-group><issn pub-type="ppub">1868-7075</issn><issn pub-type="epub">1868-7083</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40001235</article-id><article-id pub-id-type="pmc">PMC11863674</article-id>
<article-id pub-id-type="publisher-id">1811</article-id><article-id pub-id-type="doi">10.1186/s13148-025-01811-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Imaging and outcome correlates of ctDNA methylation markers in prostate cancer: a comparative, cross-sectional [&#x02076;&#x02078;Ga]Ga-PSMA-11 PET/CT study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4224-7314</contrib-id><name><surname>Kluge</surname><given-names>Kilian</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lotz</surname><given-names>Vincent</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Einspieler</surname><given-names>Holger</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Haberl</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Spielvogel</surname><given-names>Clemens</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Amereller</surname><given-names>Dominik</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kramer</surname><given-names>Gero</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Grubm&#x000fc;ller</surname><given-names>Bernhard</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Shariat</surname><given-names>Shahrokh</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Haug</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hacker</surname><given-names>Marcus</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Kenner</surname><given-names>Lukas</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff12">12</xref><xref ref-type="aff" rid="Aff13">13</xref><xref ref-type="aff" rid="Aff14">14</xref><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Egger</surname><given-names>Gerda</given-names></name><address><email>gerda.egger@meduniwien.ac.at</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff13">13</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05n3x4p02</institution-id><institution-id institution-id-type="GRID">grid.22937.3d</institution-id><institution-id institution-id-type="ISNI">0000 0000 9259 8492</institution-id><institution>Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, </institution><institution>Medical University of Vienna, </institution></institution-wrap>Vienna, Austria </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05n3x4p02</institution-id><institution-id institution-id-type="GRID">grid.22937.3d</institution-id><institution-id institution-id-type="ISNI">0000 0000 9259 8492</institution-id><institution>Christian Doppler Laboratory for Applied Metabolomics (CDLAM), </institution><institution>Medical University of Vienna, </institution></institution-wrap>Vienna, Austria </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05n3x4p02</institution-id><institution-id institution-id-type="GRID">grid.22937.3d</institution-id><institution-id institution-id-type="ISNI">0000 0000 9259 8492</institution-id><institution>Department of Pathology, </institution><institution>Medical University of Vienna, </institution></institution-wrap>Vienna, Austria </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05n3x4p02</institution-id><institution-id institution-id-type="GRID">grid.22937.3d</institution-id><institution-id institution-id-type="ISNI">0000 0000 9259 8492</institution-id><institution>Department of Urology, </institution><institution>Medical University of Vienna, </institution></institution-wrap>Vienna, Austria </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02r2nns16</institution-id><institution-id institution-id-type="GRID">grid.488547.2</institution-id><institution>Department of Urology and Andrology, </institution><institution>University Hospital Krems, </institution></institution-wrap>Krems, Austria </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04t79ze18</institution-id><institution-id institution-id-type="GRID">grid.459693.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 5929 0057</institution-id><institution>Karl Landsteiner University of Health Sciences, </institution></institution-wrap>Krems, Austria </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05r0e4p82</institution-id><institution-id institution-id-type="GRID">grid.487248.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 9340 1179</institution-id><institution>Karl Landsteiner Institute of Urology and Andrology, </institution></institution-wrap>Vienna, Austria </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05byvp690</institution-id><institution-id institution-id-type="GRID">grid.267313.2</institution-id><institution-id institution-id-type="ISNI">0000 0000 9482 7121</institution-id><institution>Department of Urology, </institution><institution>University of Texas Southwestern Medical Center, </institution></institution-wrap>Dallas, TX USA </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05k89ew48</institution-id><institution-id institution-id-type="GRID">grid.9670.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 2174 4509</institution-id><institution>Division of Urology, Department of Special Surgery, </institution><institution>The University of Jordan, </institution></institution-wrap>Amman, Jordan </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/024d6js02</institution-id><institution-id institution-id-type="GRID">grid.4491.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 116X</institution-id><institution>Department of Urology, Second Faculty of Medicine, </institution><institution>Charles University, </institution></institution-wrap>Prague, Czech Republic </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05bnh6r87</institution-id><institution-id institution-id-type="GRID">grid.5386.8</institution-id><institution-id institution-id-type="ISNI">000000041936877X</institution-id><institution>Department of Urology, </institution><institution>Weill Cornell Medical College, </institution></institution-wrap>New York, NY USA </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05n3x4p02</institution-id><institution-id institution-id-type="GRID">grid.22937.3d</institution-id><institution-id institution-id-type="ISNI">0000 0000 9259 8492</institution-id><institution>Clinical Institute of Pathology, Department for Experimental and Laboratory Animal Pathology, </institution><institution>Medical University of Vienna, </institution></institution-wrap>Vienna, Austria </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05n3x4p02</institution-id><institution-id institution-id-type="GRID">grid.22937.3d</institution-id><institution-id institution-id-type="ISNI">0000 0000 9259 8492</institution-id><institution>Comprehensive Cancer Center, </institution><institution>Medical University Vienna, </institution></institution-wrap>Vienna, Austria </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01w6qp003</institution-id><institution-id institution-id-type="GRID">grid.6583.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 9686 6466</institution-id><institution>Unit of Laboratory Animal Pathology, </institution><institution>University of Veterinary Medicine Vienna, </institution></institution-wrap>Vienna, Austria </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05kb8h459</institution-id><institution-id institution-id-type="GRID">grid.12650.30</institution-id><institution-id institution-id-type="ISNI">0000 0001 1034 3451</institution-id><institution>Department of Molecular Biology, </institution><institution>Ume&#x000e5; University, </institution></institution-wrap>Ume&#x000e5;, Sweden </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>17</volume><elocation-id>36</elocation-id><history><date date-type="received"><day>30</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>2</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">To validate the clinical utility of a previously identified circulating tumor DNA methylation marker (meth-ctDNA) panel for disease detection and survival outcomes, meth-ctDNA markers were compared to PSA levels and PSMA PET/CT findings in men with different stages of prostate cancer (PCa).</p></sec><sec><title>Methods</title><p id="Par2">122 PCa patients who underwent [&#x02076;&#x02078;Ga]Ga-PSMA-11 PET/CT and plasma sampling (03/2019&#x02013;08/2021) were analyzed. cfDNA was extracted, and a panel of 8 individual meth-ctDNA markers was queried. PET scans were qualitatively and quantitatively assessed. PSA and meth-ctDNA markers were compared to PET findings, and their relative prognostic value was evaluated.</p></sec><sec><title>Results</title><p id="Par3">PSA discriminated best between negative and tumor-indicative PET scans in all (AUC 0.77) and hormone-sensitive (hsPC) patients (0.737). In castration-resistant PCa (CRPC), the meth-ctDNA marker <italic>KLF8</italic> performed best (AUC 0.824). <italic>CHST11</italic> differentiated best between non- and metastatic scans (AUC 0.705) overall, <italic>KLF8</italic> best in hsPC and CRPC (AUC 0.662, 0.85). Several meth-ctDNA markers correlated low to moderate with the tumor volume in all (5/8) and CRPC patients (6/8), while PSA levels correlated moderately to strongly with the tumor volume in all groups (all <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). CRPC overall survival was independently associated with <italic>LDAH</italic> and PSA (<italic>p</italic>&#x02009;=&#x02009;0.0168, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001).</p></sec><sec><title>Conclusion</title><p id="Par4">The studied meth-ctDNA markers are promising for the minimally-invasive detection and prognostication of CRPC but do not allow for clinical characterization of hsPC. Prospective studies are warranted for their use in therapy response and outcome prediction in CRPC and potential incremental value for PCa monitoring in PSA-low settings.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13148-025-01811-5.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>cfDNA</kwd><kwd>DNA methylation</kwd><kwd>Epigenetics</kwd><kwd>Prostate cancer</kwd><kwd>PSMA</kwd><kwd>PET/CT</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006012</institution-id><institution>Christian Doppler Forschungsgesellschaft</institution></institution-wrap></funding-source><award-id>CD10277102</award-id><award-id>CD10277102</award-id><principal-award-recipient><name><surname>Haug</surname><given-names>Alexander</given-names></name><name><surname>Kenner</surname><given-names>Lukas</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>P32771</award-id><principal-award-recipient><name><surname>Egger</surname><given-names>Gerda</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Prostate cancer (PCa) ranks as the second most frequent malignancy in men, causing approximately 400 000 annual deaths worldwide [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par6">Due to a high degree of tumor heterogeneity, PCa survival rates vary from near-perfect 5-year overall survival (OS) rates in localized, hormone-sensitive (hsPC) to months in metastatic, castration-resistant PCa (CRPC) [<xref ref-type="bibr" rid="CR2">2</xref>]. Disease outcomes are influenced by the clinical stage, determining the feasibility of curative approaches [<xref ref-type="bibr" rid="CR3">3</xref>], and by the tumor's underlying molecular profiles [<xref ref-type="bibr" rid="CR4">4</xref>], which continuously evolve in response to systemic interventions.</p><p id="Par7">As these factors continually change throughout the disease progression [<xref ref-type="bibr" rid="CR5">5</xref>], minimally-invasive means for reassessing tumor presence, advancement, and patient prognosis, are vital for adaptive and prompt clinical management [<xref ref-type="bibr" rid="CR3">3</xref>] and rational trial design [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par8">Well-known sensitivity and specificity limitations [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>] of prostate-specific antigen (PSA) testing for PCa detection, monitoring and prognosis [<xref ref-type="bibr" rid="CR3">3</xref>], have prompted research into liquid biopsy assays as a source of PCa-specific biomarkers.</p><p id="Par9">While most efforts have focused on genomic or transcriptomic analysis of circulating tumor DNA (ctDNA) or cells [<xref ref-type="bibr" rid="CR9">9</xref>], epigenetic tumor DNA methylation modifications occur early, are stable and frequent [<xref ref-type="bibr" rid="CR10">10</xref>], making them an attractive alternative source for high-sensitivity, PCa-specific, diagnostic and prognostic biomarkers [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par10">We have previously also investigated the suitability of such ctDNA methylation markers for PCa-specific diagnostics and identified a panel of eight novel, high-potential ctDNA targets in the context of PCa [<xref ref-type="bibr" rid="CR16">16</xref>]. As novel biomarkers are developed, their clinical characterization through contextualization with established diagnostic and prognostic approaches is key to informing their best use cases. We, therefore, sought to comparatively benchmark the previously identified ctDNA methylation marker panel against PSA levels using prostate-specific membrane antigen (PSMA) positron-emission-tomography/computed-tomography (PET/CT), the current imaging gold standard for PCa detection [<xref ref-type="bibr" rid="CR17">17</xref>] and prognostic in itself [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par11">Our aim was to evaluate their relative predictive value for clinically actionable disease on PSMA imaging and their prognostic potential for OS outcomes.</p><p id="Par12">We hypothesized that the meth-ctDNA markers are predictive of metastasis and survival outcomes in CRPC.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design</title><p id="Par13">From March 2019 to August 2021, a total of 187 men with histologically confirmed PCa underwent [&#x02076;&#x02078;Ga]Ga-PSMA-11 PET/CT imaging and provided blood samples [<xref ref-type="bibr" rid="CR20">20</xref>] of which 122 patients were included in this analysis (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Recruitment followed an all-comers approach, with each participant providing written informed consent (IRB-ID: 1649/2016).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Consort diagram and unsupervised clustering analysis. <bold>A</bold> Illustrates the study's inclusion and exclusion criteria. <bold>B</bold> Imaging determined disease extent clustering of PMR-values according to castration status</p></caption><graphic xlink:href="13148_2025_1811_Fig1_HTML" id="MO1"/></fig></p><p id="Par14">Retrospective data collection of PSA levels, castration state, treatment history and survival data (via the national health statistical service, censorization 27.02.2024) was conducted.</p><p id="Par15">The endpoints were (a) differences and associations of meth-ctDNA markers and PSA levels with PSMA PET findings per castration status groups, (b) the prognostic association of meth-ctDNA markers levels, PSMA-TV and PSA with OS in CRPC patients. (Supplemental Material&#x02014;Methods).</p></sec><sec id="Sec4"><title>Plasma sample collection, cfDNA extraction, quantification and methylation-sensitive restriction enzyme qPCR (MSRE-qPCR)</title><p id="Par16">Sample collection and storage were previously described [<xref ref-type="bibr" rid="CR20">20</xref>]. In brief, cell-free DNA (cfDNA) BCT tubes (Streck Inc., USA) were used for blood sampling prior to tracer injection. cfDNA was extracted from 4&#x000a0;ml of plasma employing QIAamp Circulating Nucleic Acid Kits (QIAGEN, the Netherlands) and quantified using a Qubit 3 Fluorometer (Invitrogen, USA).</p><p id="Par17">MSRE-qPCR primers (Table <xref rid="MOESM1" ref-type="media">S1</xref>) and workflow were previously described [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Briefly, each cfDNA sample was split for methylation-sensitive enzymatic and mock digestion (75%:25%, respectively). Digestion reactions contained a mixture of four different MSREs, while mock digestions contained DNAse-free H<sub>2</sub>O instead of enzymes and served as DNA input normalization. Fully Methylated Human DNA (Zymo Research, USA) was used as methylation level reference control. All reactions were incubated at 37&#x000a0;&#x000b0;C for digestion, followed by a thermal inactivation, volume-reduction and multiplexed preamplification. qPCRs were performed using the Luna Universal qPCR Master Mix (New England Biolabs, USA) on a Biorad CFX96 Touch Real-Time PCR Detection System (Biorad Laboratories, USA).</p><p id="Par18">Sample quantities were calculated using standard curves of genomic DNA from Cq values. Percentage of Methylation Ratios (PMR) was calculated using fully methylated DNA as the reference control. (Supplemental Material&#x02014;Methods).</p></sec><sec id="Sec5"><title>Imaging protocol and image analysis</title><p id="Par19">The imaging protocol and analysis was previously described [<xref ref-type="bibr" rid="CR20">20</xref>]. In brief, imaging was performed on a Biograph TruePoint PET/CT scanner (Siemens Healthineers, Germany) an hour after i.v. [&#x02076;&#x02078;Ga]Ga-PSMA-11 injection (First acquisition: CT, Second acquisition PET (3&#x02013;4 bed positions)). Next, images were reconstructed, scatter and attenuation corrected. Two nuclear medicine physicians used the Hybrid 3D software (v.4.0.0, Hermes Medical Solutions, Sweden) to qualitatively identify and semi-automatically delineate PSMA-expressing lesions by anatomical location to calculate the aggregated PSMA-positive tumor volume (PSMA-TV). PSMA-positive lesions were identified by qualitative PET scan analysis informed by the liver uptake, with lesions equal to or above liver uptake assumed malignant. Metastatic and non-metastatic disease state definitions were PSMA PET-based [<xref ref-type="bibr" rid="CR22">22</xref>]<italic>.</italic> (Supplemental Material&#x02014;Methods).</p></sec><sec id="Sec6"><title>Data analysis</title><p id="Par20">Numeric variables are expressed as mean (&#x000b1;&#x02009;SD), discrete outcomes as absolute and relative (%) frequencies. Shapiro&#x02013;Wilk and Levene&#x02019;s tests assessed the normality and heteroskedasticity of continuous variables.</p><p id="Par21">Data distribution informed, numeric variables were compared with the Mann&#x02013;Whitney-U or Kruskal&#x02013;Wallis tests, discrete outcomes with Chi-squared or Fisher&#x02019;s exact tests.</p><p id="Par22">Area under the receiver-operating-characteristic (AUC) curves (ROC) with 95% confidence intervals (CI) assessed the ability to predict PSMA PET findings. Correlations were evaluated using Spearman's coefficient. Dunn&#x02013;Bonferronis corrections were used to adjust for multiple testing.</p><p id="Par23">For the survival analysis, PMR, PSA and PSMA-TV values were dichotomized using the medians of the overall and the CPRC cohorts. Differences in OS between the respective high and low groups were compared using the non-parametric Logrank test, with censoring applied at the time of the last follow-up. Only univariate significant features were included in the multivariate Cox regression after testing data for multicollinearity and proportional hazards using the Belsley&#x02013;Kuh&#x02013;Welsch technique and Schoenfeld residuals. The alpha risk was set to 5% for all analyses. Statistical analysis was performed with EasyMedStat (version 3.32; <ext-link ext-link-type="uri" xlink:href="http://www.easymedstat.com">www.easymedstat.com</ext-link>). (Supplemental Material&#x02014;Methods).</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Cohort</title><p id="Par24">122 PCa patients (age 70.9&#x02009;&#x000b1;&#x02009;7.6&#x000a0;years; hsPC (N&#x02009;=&#x02009;58), CRPC (N&#x02009;=&#x02009;64)) who underwent plasma sample collection and [&#x02076;&#x02078;Ga]Ga-PSMA-11 PET/CT imaging were included in this study (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Patient characteristics are presented in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.
<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Demographic and clinical patient data</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable</th><th align="left">Total<break/>N&#x02009;=&#x02009;122</th><th align="left">hsPC<break/>N&#x02009;=&#x02009;58</th><th align="left">CRPC<break/>N&#x02009;=&#x02009;64</th><th align="left"><italic>p</italic>-Value</th></tr></thead><tbody><tr><td align="left"><bold>Age [y]</bold></td><td align="left"><p>70.9 (&#x000b1;&#x02009;7.6)</p><p>Range: (49.0; 85.0)</p></td><td align="left"><p>70.0 (&#x000b1;&#x02009;7.8)</p><p>Range: (50.0; 85.0)</p></td><td align="left"><p>71.8 (&#x000b1;&#x02009;7.3)</p><p>Range: (49.0; 85.0)</p></td><td char="." align="char">0.201</td></tr><tr><td align="left"><bold>Tracer dose [Mbq]</bold></td><td align="left"><p>185.1&#x02009;&#x000b1;&#x02009;19.5</p><p>Range: (134.0; 300.0)</p></td><td align="left"><p>186.1 (&#x000b1;&#x02009;22.0)</p><p>Range: (134.0; 300.0)</p></td><td align="left"><p>184.1 (&#x000b1;&#x02009;17.0)</p><p>Range: (149.0; 263.0)</p></td><td char="." align="char">0.802</td></tr><tr><td align="left"><bold>PSA [ng/mL]</bold></td><td align="left"><p>102.65&#x02009;&#x000b1;&#x02009;448.03</p><p>Range: (0.01; 3689.0)</p></td><td align="left"><p>6.63 (&#x000b1;&#x02009;12.29)</p><p>Range: (0.18; 51.2)</p></td><td align="left"><p>189.67 (&#x000b1;&#x02009;607.63)</p><p>Range: (0.01; 3689.0)</p></td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left"><bold>DNA methylation markers</bold></td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;<italic>AKR1B1</italic> [PMR]</td><td align="left"><p>2.82 (&#x000b1;&#x02009;12.52)</p><p>Range: (1e-06; 80.66)</p></td><td align="left"><p>0.00039 (&#x000b1;&#x02009;0.00198)</p><p>Range: (1e-06; 0.015)</p></td><td align="left"><p>5.38 (&#x000b1;&#x02009;16.94)</p><p>Range: (1e-06; 80.66)</p></td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x000a0;<italic>CHST11 </italic>[PMR]</td><td align="left"><p>1.75 (&#x000b1;&#x02009;8.6)</p><p>Range: (0.0; 83.77)</p></td><td align="left"><p>0.00035 (&#x000b1;&#x02009;0.0018)</p><p>Range: (0.0; 0.0113)</p></td><td align="left"><p>3.34 (&#x000b1;&#x02009;11.69)</p><p>Range: (0.0; 83.77)</p></td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x000a0;<italic>CRABP2</italic> [PMR]</td><td align="left"><p>0.49 (&#x000b1;&#x02009;2.36)</p><p>Range: (1.7e-05; 20.96)</p></td><td align="left"><p>0.0813 (&#x000b1;&#x02009;0.102)</p><p>Range: (0.000117; 0.597)</p></td><td align="left"><p>0.865 (&#x000b1;&#x02009;3.22)</p><p>Range: (1.7e-05; 20.96)</p></td><td char="." align="char">0.062</td></tr><tr><td align="left">&#x000a0;<italic>CUGBP2</italic> [PMR]*</td><td align="left"><p>0.13 (&#x000b1;&#x02009;1.05)</p><p>Range: (0.0; 10.75)</p></td><td align="left"><p>0.00637 (&#x000b1;&#x02009;0.0475)</p><p>Range: (0.0; 0.361)</p></td><td align="left"><p>0.247 (&#x000b1;&#x02009;1.46)</p><p>Range: (0.0; 10.75)</p></td><td char="." align="char">0.086</td></tr><tr><td align="left">&#x000a0;<italic>KLF8 </italic>[PMR]</td><td align="left"><p>3.3 (&#x000b1;&#x02009;9.73)</p><p>Range: (0.00317; 45.07)</p></td><td align="left"><p>0.238 (&#x000b1;&#x02009;0.827)</p><p>Range: (0.00317; 6.28)</p></td><td align="left"><p>6.08 (&#x000b1;&#x02009;12.83)</p><p>Range: (0.00664; 45.07)</p></td><td char="." align="char">0.001</td></tr><tr><td align="left">&#x000a0;<italic>LDAH</italic> [PMR]</td><td align="left"><p>3.41 (&#x000b1;&#x02009;11.79)</p><p>Range: (4.1e-05; 71.99)</p></td><td align="left"><p>0.0104 (&#x000b1;&#x02009;0.0596)</p><p>Range: (4.1e-05; 0.452)</p></td><td align="left"><p>6.5 (&#x000b1;&#x02009;15.71)</p><p>Range: (4.4e-05; 71.99)</p></td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x000a0;<italic>PCDHGC4 </italic>[PMR]</td><td align="left"><p>2.23 (&#x000b1;&#x02009;7.88)</p><p>Range: (1e-06; 42.61)</p></td><td align="left"><p>0.0118 (&#x000b1;&#x02009;0.0355)</p><p>Range: (1e-06; 0.254)</p></td><td align="left"><p>4.25 (&#x000b1;&#x02009;10.52)</p><p>Range: (1e-06; 42.61)</p></td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x000a0;<italic>TNFAIP8 </italic>[PMR]</td><td align="left"><p>1.06 (&#x000b1;&#x02009;5.66)</p><p>Range: (0.0; 58.36)</p></td><td align="left"><p>0.397 (&#x000b1;&#x02009;0.675)</p><p>Range: (5.5e-05; 3.69)</p></td><td align="left"><p>1.66 (&#x000b1;&#x02009;7.77)</p><p>Range: (0.0; 58.36)</p></td><td char="." align="char">0.737</td></tr><tr><td align="left">&#x000a0;<bold>PSMA-TV [cm3]</bold></td><td align="left"><p>116.5&#x02009;&#x000b1;&#x02009;305.5</p><p>Range: (0.0; 1597.7)</p></td><td align="left"><p>16.2 (&#x000b1;&#x02009;86.5)</p><p>Range: (0.0; 659.1)</p></td><td align="left"><p>207.4 (&#x000b1;&#x02009;392.8)</p><p>Range: (0.0; 1597.7)</p></td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left"><bold>Disease extent</bold></td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x000a0;Non</td><td align="left">25 (20.49%)</td><td align="left">16 (27.59%)</td><td align="left">9 (14.06%)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Localized</td><td align="left">21 (17.21%)</td><td align="left">16 (27.59%)</td><td align="left">5 (7.81%)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Metastatic</td><td align="left">76 (62.3%)</td><td align="left">26 (44.83%)</td><td align="left">50 (78.12%)</td><td char="." align="char"/></tr><tr><td align="left"><bold>PSMA-TV [cm3] per disease extent</bold></td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Localized</td><td align="left"><p>4.5 (&#x000b1;&#x02009;4.4)</p><p>Range: (0.2; 15.4)</p></td><td align="left"><p>4.26 (&#x000b1;&#x02009;4.1)</p><p>Range: (0.2; 14.83)</p></td><td align="left"><p>5.28 (&#x000b1;&#x02009;5.8)</p><p>Range: (0.8; 15.38)</p></td><td char="." align="char">0.836</td></tr><tr><td align="left">&#x000a0;Metastatic</td><td align="left"><p>185.7 (&#x000b1;&#x02009;370.5)</p><p>Range: (0.2; 1597.7)</p></td><td align="left"><p>33.5 (&#x000b1;&#x02009;128.4)</p><p>Range: (0.2; 659.1)</p></td><td align="left"><p>264.9 (&#x000b1;&#x02009;427.7)</p><p>Range: (0.3; 1597.7)</p></td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left"><bold>PSMA-positive lesions</bold></td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Any lesion</td><td align="left">97 (79.51%)</td><td align="left">42 (72.41%)</td><td align="left">55 (85.94%)</td><td char="." align="char">0.104</td></tr><tr><td align="left">&#x000a0;Prostate</td><td align="left">39 (31.97%)</td><td align="left">23 (39.66%)</td><td align="left">16 (25.0%)</td><td char="." align="char">0.124</td></tr><tr><td align="left">&#x000a0;Lymph node</td><td align="left">51 (41.8%)</td><td align="left">19 (32.76%)</td><td align="left">32 (50.0%)</td><td char="." align="char">0.081</td></tr><tr><td align="left">&#x000a0;Bone</td><td align="left">51 (41.8%)</td><td align="left">10 (17.24%)</td><td align="left">41 (64.06%)</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x000a0;Organ</td><td align="left">18 (14.75%)</td><td align="left">4 (6.9%)</td><td align="left">14 (21.88%)</td><td char="." align="char">0.023</td></tr><tr><td align="left"><bold>Hormonal therapies while PET</bold></td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x000a0;Yes</td><td align="left">48 (39.34%)</td><td align="left">4 (6.9%)</td><td align="left">44 (68.75%)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;No</td><td align="left">68 (55.7%)</td><td align="left">51 (87.93%)</td><td align="left">17 (26.56%)</td><td char="." align="char"/></tr><tr><td align="left"><bold>Cytotoxic therapies while PET</bold></td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">0.403</td></tr><tr><td align="left">&#x000a0;Yes</td><td align="left">4 (3.3%)</td><td align="left">1 (1.72%)</td><td align="left">3 (4.69%)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;No</td><td align="left">114 (93.4%)</td><td align="left">54 (93.1%)</td><td align="left">60 (93.75%)</td><td char="." align="char"/></tr><tr><td align="left"><bold>Therapies after PET</bold></td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x000a0;Local</td><td align="left">29 (39.19%)</td><td align="left">22 (57.89%)</td><td align="left">7 (19.44%)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Local&#x02009;+&#x02009;ADT</td><td align="left">5 (6.76%)</td><td align="left">5 (13.16%)</td><td align="left">0 (0.0%)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;ADT</td><td align="left">17 (22.97%)</td><td align="left">8 (21.05%)</td><td align="left">9 (25.0%)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;CHT</td><td align="left">3 (4.05%)</td><td align="left">0 (0.0%)</td><td align="left">3 (8.33%)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;CHT&#x02009;+&#x02009;ADT</td><td align="left">2 (2.7%)</td><td align="left">1 (2.63%)</td><td align="left">1 (2.78%)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Lu177</td><td align="left">17 (22.97%)</td><td align="left">1 (2.63%)</td><td align="left">16 (44.44%)</td><td char="." align="char"/></tr><tr><td align="left">&#x000a0;Study</td><td align="left">1 (1.35%)</td><td align="left">1 (2.63%)</td><td align="left">0 (0.0%)</td><td char="." align="char"/></tr><tr><td align="left"><bold>Time since diagnosis [y]</bold></td><td align="left"><p>5.44&#x02009;&#x000b1;&#x02009;5.85</p><p>Range: (0.0; 21.0)</p><p>N&#x02009;=&#x02009;111</p></td><td align="left"><p>3.58 (&#x000b1;&#x02009;4.67)</p><p>Range: (0.0; 20.0)</p><p>N&#x02009;=&#x02009;55</p></td><td align="left"><p>7.27 (&#x000b1;&#x02009;6.39)</p><p>Range: (0.0; 21.0)</p><p>N&#x02009;=&#x02009;56</p></td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left"><bold>Mean Follow-Up [m]</bold></td><td align="left">24.88&#x02009;&#x000b1;&#x02009;16.56</td><td align="left">21.0&#x02009;&#x000b1;&#x02009;16.33</td><td align="left">29.15&#x02009;&#x000b1;&#x02009;15.88</td><td char="." align="char">0.011</td></tr><tr><td align="left"/><td align="left">Range: (0.0; 58.75)</td><td align="left">Range: (0.43; 58.75)</td><td align="left">Range: (0.0; 51.87)</td><td char="." align="char"/></tr></tbody></table><table-wrap-foot><p>Qualitative data represented as numbers and percentages; Continuous data represented as mean, standard deviation and range; Group comparisons with respect to hsPC and CRPC. *Two CUGBP2 outlier values were excluded from the analysis</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec9"><title>ctDNA methylation marker and PSA level&#x02019;s discriminatory value to distinguish between positive and negative PSMA PET</title><p id="Par25">In the overall cohort, significant differences between patients with negative and tumor-indicative PSMA scans were found for 2/8 (25%) of the analyzed meth-ctDNA markers (<italic>CHST11</italic> (<italic>p</italic>&#x02009;=&#x02009;0.007), <italic>KLF8</italic> (<italic>p</italic>&#x02009;=&#x02009;0.026)) and PSA (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), with the highest AUC for PSA (AUC 0.77, CI&#x02009;=&#x02009;[0.683; 0.857]) (Figs.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A, <xref rid="MOESM1" ref-type="media">S2</xref>, Tables <xref rid="MOESM1" ref-type="media">S2</xref>, <xref rid="MOESM1" ref-type="media">S4</xref>, <xref rid="MOESM1" ref-type="media">S17</xref>). In the hsPC cohort, no meth-ctDNA marker and merely PSA differed significantly (<italic>p</italic>&#x02009;=&#x02009;0.006) between patients with positive and negative PSMA scans, which exhibited an AUC of 0.737 (CI&#x02009;=&#x02009;[0.609; 0.866]) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A, <xref rid="MOESM1" ref-type="media">S3</xref>, Tables <xref rid="MOESM1" ref-type="media">S2</xref>, <xref rid="MOESM1" ref-type="media">S5</xref>, <xref rid="MOESM1" ref-type="media">S17</xref>). While in CRPC patients 3/8 (32.5%) of the meth-ctDNA markers (<italic>CHST11</italic> (<italic>p</italic>&#x02009;=&#x02009;0.011), <italic>CRABP2</italic> (<italic>p</italic>&#x02009;=&#x02009;0.013), <italic>KLF8</italic> (<italic>p</italic>&#x02009;=&#x02009;0.002)) and PSA (<italic>p</italic>&#x02009;=&#x02009;0.006) differed significantly with <italic>KLF8</italic> exhibiting the highest AUC of 0.824 (CI&#x02009;=&#x02009;[0.652; 0.92]) (Figs.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A, <xref rid="MOESM1" ref-type="media">S4</xref>, Tables <xref rid="MOESM1" ref-type="media">S2</xref>, <xref rid="MOESM1" ref-type="media">S6</xref>, <xref rid="MOESM1" ref-type="media">S17</xref>).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>AUC (95% CI) values under the ROC depict the discriminatory value of the ctDNA PMR and PSA values to distinguish between <bold>A</bold> No and any tumor-indicative lesion and <bold>B</bold> No or Local and metastasis-indicative lesions on PSMA PET. Significant differing variables between globally positive and negative as well as non- and metastatic PSMA scans in dark red</p></caption><graphic xlink:href="13148_2025_1811_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec10"><title>ctDNA methylation marker and PSA level&#x02019;s discriminatory value to identify metastatic disease on PSMA PET</title><p id="Par26">In all patients, 5/8 (62.5%) of the analyzed meth-ctDNA markers (<italic>AKR1B1</italic> (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), <italic>CHST11</italic> (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), <italic>KLF8</italic> (<italic>p</italic>&#x02009;=&#x02009;0.016), <italic>LDAH</italic> (<italic>p</italic>&#x02009;=&#x02009;0.007), <italic>PCDHGC4</italic> (<italic>p</italic>&#x02009;=&#x02009;0.002)) and PSA levels (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) differed significantly between patients with non-metastatic and metastatic disease on the PSMA scans, with the highest AUC under the ROC achieved by <italic>CHST11</italic> (AUC&#x02014;0.705, CI&#x02009;=&#x02009;[0.618; 0.793]) (Figs.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B, <xref rid="MOESM1" ref-type="media">S5</xref>, Tables <xref rid="MOESM1" ref-type="media">S2</xref>, <xref rid="MOESM1" ref-type="media">S7</xref>&#x02013;<xref rid="MOESM1" ref-type="media">9</xref>, <xref rid="MOESM1" ref-type="media">S18</xref>).</p><p id="Par27">In hsPC patients, only 1/8 (12.5%) of the meth-ctDNA markers, specifically <italic>KLF8</italic> (<italic>p</italic>&#x02009;=&#x02009;0.035), differed significantly between patients with non-metastatic and metastatic PSMA scans, while PSA levels did not, with an AUC of <italic>KLF8</italic> (AUC&#x02014;0.662, CI&#x02009;=&#x02009;[0.519; 0.806]) (Figs.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B, <xref rid="MOESM1" ref-type="media">S7</xref>, Tables <xref rid="MOESM1" ref-type="media">S2</xref>, <xref rid="MOESM1" ref-type="media">S10</xref>&#x02013;<xref rid="MOESM1" ref-type="media">12</xref>, <xref rid="MOESM1" ref-type="media">S18</xref>).</p><p id="Par28">In the CRPC group, 6/8 (75%) of meth-ctDNA markers (<italic>AKR1B1</italic> (<italic>p</italic>&#x02009;=&#x02009;0.007), <italic>CHST11</italic> (<italic>p</italic>&#x02009;=&#x02009;0.001), <italic>CRABP2</italic> (<italic>p</italic>&#x02009;=&#x02009;0.004), <italic>KLF8</italic> (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), <italic>LDAH</italic> (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.026), <italic>PCDHGC4</italic> (<italic>p</italic>&#x02009;=&#x02009;0.018)) and PSA levels (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) differed significantly between non-metastatic and metastatic PSMA scans, with the highest AUC achieved by <italic>KLF8</italic> (AUC 0.85, CI&#x02009;=&#x02009;[0.743; 0.957]) (Figs.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B, <xref rid="MOESM1" ref-type="media">S9</xref>, Tables <xref rid="MOESM1" ref-type="media">S2</xref>, <xref rid="MOESM1" ref-type="media">S13</xref>&#x02013;<xref rid="MOESM1" ref-type="media">15</xref>, <xref rid="MOESM1" ref-type="media">S18</xref>).</p></sec><sec id="Sec11"><title>Relationship of ctDNA methylation marker and PSA levels with the PET PSMA-TV</title><p id="Par29">Positive associations between meth-ctDNA markers and PSMA-TV were found in the overall cohort and CRPC group; however, not in the hsPC cohort. In the overall cohort, low positive correlations were observed for <italic>AKR1B1</italic> (r&#x02009;=&#x02009;0.4, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), <italic>CHST11</italic> (r&#x02009;=&#x02009;0.44, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), <italic>KLF8</italic> (r&#x02009;=&#x02009;0.37, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), <italic>LDAH</italic> (r&#x02009;=&#x02009;0.44, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and <italic>PCDHGC4</italic> (r&#x02009;=&#x02009;0.46, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and PSMA-TV. In the CRPC group, moderate positive correlations were observed for <italic>AKR1B1</italic> (r&#x02009;=&#x02009;0.56, p&#x02009;&#x0003c;&#x02009;0.001), <italic>CHST11</italic> (r&#x02009;=&#x02009;0.58, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), <italic>CRABP2</italic> (r&#x02009;=&#x02009;0.44, <italic>p</italic>&#x02009;=&#x02009;0.002), <italic>KLF8</italic> (r&#x02009;=&#x02009;0.62, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), <italic>LDAH</italic> (r&#x02009;=&#x02009;0.57, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and <italic>PCDHGC4</italic> (r&#x02009;=&#x02009;0.51, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and PSMA-TV. No significant negative correlation was found between any meth-ctDNA marker and PSMA-TV in any group.</p><p id="Par30">Moderate to strong positive correlations were observed between PSA levels with PSMA-TV in all groups (r&#x02009;=&#x02009;0.71 (overall), r&#x02009;=&#x02009;0.58 (hsPC), r&#x02009;=&#x02009;0.76 (CRPC), all <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). A visual overview of the results is shown in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> and listed in Table <xref rid="MOESM1" ref-type="media">S18</xref>.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Relationship of meth-ctDNA PMR and PSA values with the PSMA-TV according to castration statuses. Red bars indicate negative correlations, green bars positive correlations. Only significant p-values after Bonferroni multiple-testing adjustments are displayed</p></caption><graphic xlink:href="13148_2025_1811_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec12"><title>Survival analysis</title><p id="Par31">Of the 64 patients included in the OS analysis, 28 patients (43.75%) events were observed, while 36 patients (56.25%) were censored at the last follow-up. The median duration of follow-up was 19.92&#x000a0;months (IQR 27.62). At 12&#x000a0;months, the OS was 71.9% (CI&#x02009;=&#x02009;[59.1, 81.3]) and at 24&#x000a0;months, the OS was 62.5% (CI&#x02009;=&#x02009;[49.5, 73.1]).</p><p id="Par32">Patients with high and low <italic>LDAH</italic> values (stratified on the overall cohort) (hazard ratio (HR)&#x02009;=&#x02009;7.91, CI&#x02009;=&#x02009;[1.28, 49.05], <italic>p</italic>&#x02009;=&#x02009;0.0263) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A, Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) and patients with high and low&#x000a0;PSA levels (stratified on the CRPC cohort) (HR&#x02009;=&#x02009;6.29, CI&#x02009;=&#x02009;[1.37, 28.86], <italic>p</italic>&#x02009;=&#x02009;0.0181]) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>B, Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) had significant hazard differences. Both <italic>LDAH</italic> and PSA levels remained independently associated with OS in CRPC patients when analyzed in a comparative multivariate analysis (HR&#x02009;=&#x02009;4.42, CI&#x02009;=&#x02009;[1.31, 14.94], <italic>p</italic>&#x02009;=&#x02009;0.0168 and HR&#x02009;=&#x02009;10.82, CI&#x02009;=&#x02009;[3.21, 36.45], <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, respectively) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>C, Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). For the univariate log-rank analysis results, please refer to Figs <xref rid="MOESM1" ref-type="media">S11</xref>, <xref rid="MOESM1" ref-type="media">S12</xref> and Tables <xref rid="MOESM1" ref-type="media">S19</xref>, <xref rid="MOESM1" ref-type="media">20</xref>.<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Forest plots depicting the HR of the explanatory DNA methylation markers, PSA and PSMA-TV values and age. High and low group stratification by median of the overall cohort <bold>A</bold> and of the CRPC group <bold>B</bold>. <bold>C</bold> depicts the HRs of significant covariates from analyses <bold>A</bold> and <bold>B</bold>, suggesting an independent association of <italic>LDAH</italic> and PSA levels with OS in CRPC patients</p></caption><graphic xlink:href="13148_2025_1811_Fig4_HTML" id="MO4"/></fig><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Multivariate Cox regression of the binarily stratified explanatory DNA methylation markers, PSA and PSMA-TV values and age</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Covariate</th><th align="left">Hazard Ratio<break/>[95% CI]<break/>[overall]</th><th align="left"><italic>p</italic>-Value</th><th align="left">Hazard Ratio<break/>[95% CI]<break/>[CRPC]</th><th align="left"><italic>p</italic>-Value</th><th align="left">Hazard Ratio<break/>[95% CI]<break/>[comparative]</th><th align="left"><italic>p</italic>-Value</th></tr></thead><tbody><tr><td align="left" colspan="7"><bold>Age</bold></td></tr><tr><td align="left">Risk for each 1-unit increase</td><td align="left">0.978 [0.917; 1.04]</td><td char="." align="char">0.499</td><td align="left">0.973 [0.912; 1.04]</td><td char="." align="char">0.398</td><td align="left">&#x02212;</td><td char="." align="char">&#x02212;</td></tr><tr><td align="left" colspan="7"><bold><italic>AKR1B1</italic></bold></td></tr><tr><td align="left">high</td><td align="left">0.347 [0.0611; 1.98]</td><td char="." align="char">0.233</td><td align="left">0.96 [0.175; 5.25]</td><td char="." align="char">0.962</td><td align="left">&#x02212;</td><td char="." align="char">&#x02212;</td></tr><tr><td align="left">low</td><td align="left">2.88 [0.506; 16.37]</td><td char="." align="char">0.233</td><td align="left">1.04 [0.19; 5.7]</td><td char="." align="char">0.962</td><td align="left">&#x02212;</td><td char="." align="char">&#x02212;</td></tr><tr><td align="left" colspan="7"><bold><italic>CHST11</italic></bold></td></tr><tr><td align="left">high</td><td align="left">2.16 [0.625; 7.45]</td><td char="." align="char">0.224</td><td align="left">2.28 [0.444; 11.68]</td><td char="." align="char">0.324</td><td align="left">&#x02212;</td><td char="." align="char">&#x02212;</td></tr><tr><td align="left">low</td><td align="left">0.463 [0.134; 1.6]</td><td char="." align="char">0.224</td><td align="left">0.439 [0.0856; 2.25]</td><td char="." align="char">0.324</td><td align="left">&#x02212;</td><td char="." align="char">&#x02212;</td></tr><tr><td align="left" colspan="7"><bold><italic>CRABP2</italic></bold></td></tr><tr><td align="left">high</td><td align="left">1.12 [0.446; 2.82]</td><td char="." align="char">0.807</td><td align="left">1.53 [0.507; 4.63]</td><td char="." align="char">0.449</td><td align="left">&#x02212;</td><td char="." align="char">&#x02212;</td></tr><tr><td align="left">low</td><td align="left">0.891 [0.355; 2.24]</td><td char="." align="char">0.807</td><td align="left">0.653 [0.216; 1.97]</td><td char="." align="char">0.449</td><td align="left">&#x02212;</td><td char="." align="char">&#x02212;</td></tr><tr><td align="left" colspan="7"><bold><italic>KLF8</italic></bold></td></tr><tr><td align="left">high</td><td align="left">4.06 [0.984; 16.72]</td><td char="." align="char">0.0527</td><td align="left">2.22 [0.472; 10.48]</td><td char="." align="char">0.313</td><td align="left">&#x02212;</td><td char="." align="char">&#x02212;</td></tr><tr><td align="left">low</td><td align="left">0.247 [0.0598; 1.02]</td><td char="." align="char">0.0527</td><td align="left">0.45 [0.0954; 2.12]</td><td char="." align="char">0.313</td><td align="left">&#x02212;</td><td char="." align="char">&#x02212;</td></tr><tr><td align="left" colspan="7"><bold><italic>LDAH</italic></bold></td></tr><tr><td align="left">high</td><td align="left">7.91 [1.28; 49.05]</td><td char="." align="char">0.0263</td><td align="left">0.694 [0.125; 3.86]</td><td char="." align="char">0.676</td><td align="left">4.42 [1.31; 14.94]</td><td char="." align="char">0.0168</td></tr><tr><td align="left">low</td><td align="left">0.126 [0.0204; 0.783]</td><td char="." align="char">0.0263</td><td align="left">1.44 [0.259; 8.02]</td><td char="." align="char">0.676</td><td align="left">0.226 [0.067; 0.765]</td><td char="." align="char">0.0168</td></tr><tr><td align="left" colspan="7"><bold><italic>PCDHGC4</italic></bold></td></tr><tr><td align="left">high</td><td align="left">2.08 [0.545; 7.92]</td><td char="." align="char">0.285</td><td align="left">1.77 [0.401; 7.78]</td><td char="." align="char">0.452</td><td align="left">&#x02212;</td><td char="." align="char">&#x02212;</td></tr><tr><td align="left">low</td><td align="left">0.482 [0.126; 1.84]</td><td char="." align="char">0.285</td><td align="left">0.566 [0.128; 2.5]</td><td char="." align="char">0.452</td><td align="left">&#x02212;</td><td char="." align="char">&#x02212;</td></tr><tr><td align="left" colspan="7"><bold>PSA</bold></td></tr><tr><td align="left">high</td><td align="left">1.28 [0.193; 8.44]</td><td char="." align="char">0.799</td><td align="left">6.29 [1.37; 28.86]</td><td char="." align="char">0.0181</td><td align="left">10.82 [3.21; 36.45]</td><td char="." align="char">0.000012</td></tr><tr><td align="left">low</td><td align="left">0.783 [0.119; 5.17]</td><td char="." align="char">0.799</td><td align="left">0.159 [0.0346; 0.731]</td><td char="." align="char">0.0181</td><td align="left">0.092 [0.027; 0.311]</td><td char="." align="char">0.000012</td></tr><tr><td align="left" colspan="7"><bold>PSMA-TV</bold></td></tr><tr><td align="left">high</td><td align="left">5.46 [0.52; 57.27]</td><td char="." align="char">0.157</td><td align="left">2.14 [0.396; 11.51]</td><td char="." align="char">0.377</td><td align="left">&#x02212;</td><td char="." align="char">&#x02212;</td></tr><tr><td align="left">low</td><td align="left">0.183 [0.0175; 1.92]</td><td char="." align="char">0.157</td><td align="left">0.468 [0.0869; 2.52]</td><td char="." align="char">0.377</td><td align="left">&#x02212;</td><td char="." align="char">&#x02212;</td></tr></tbody></table><table-wrap-foot><p>Group stratification by median of the overall cohort ([overall]), and CRPC group ([CRPC]), except for age in years. Results for the comparative regression analysis incorporating significant findings of overall and CRPC group stratified covariates in the two rightmost columns</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec13"><title>Discussion</title><p id="Par33">Liquid biopsy approaches hold the promise to advance PCa management through minimally-invasive, repeatable molecular cancer profiling to enable more accurate disease diagnosis, monitoring, and prognostication. Particularly, epigenetic ctDNA methylation modifications are an attractive source of PCa-specific biomarkers, as they occur early, are stable and more abundant than somatic gene alterations [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>]. We previously investigated [<xref ref-type="bibr" rid="CR16">16</xref>] the suitability of such ctDNA methylation markers for PCa-specific diagnosis and prognosis and identified a panel of eight high-potential targets. To validate their clinical utility, we compared these markers against PSA levels and PSMA PET/CT findings to assess their relative predictive value for clinically actionable disease presence and survival outcomes.</p><p id="Par34">In the setting of local or oligometastatic hsPC, disease-, risk- and extent-specific biomarkers could enable accurate primary screening practices [<xref ref-type="bibr" rid="CR7">7</xref>], refine active surveillance strategies, and help inform clinical management in curative and salvage settings [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par35">In our hsPC group, however, no meth-ctDNA marker accurately discriminated between patients with no or any disease on imaging, unlike PSA, while only <italic>KLF8</italic> differed between hsPC patients with non- and metastatic PSMA scans (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Upon closer examination of the <italic>KLF8</italic> value distribution between the non- and metastatic groups (Figure <xref rid="MOESM1" ref-type="media">S7</xref>), however, no definite differentiation for the majority of patients was apparent, suggesting that the observed difference would not broadly translate into future clinical applicability. Similarly, no meth-ctDNA marker exhibited any tangible relationship with PSMA-TV in patients with hsPC, while PSA correlated with the overall tumor load (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).</p><p id="Par36">This is in line with our previous observations [<xref ref-type="bibr" rid="CR16">16</xref>] and various reports [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR24">24</xref>] of low ctDNA abundance using genomic [<xref ref-type="bibr" rid="CR25">25</xref>] or epigenetic [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>] modes of analysis in localized and low-volume metastatic hsPC disease. Bjerre et al. [<xref ref-type="bibr" rid="CR12">12</xref>] investigated the diagnostic and prognostic potential of a three-gene methylation ctDNA signature consisting of <italic>DOCK2, HAPLN3,</italic> and <italic>FBXO30</italic>. This signature was able to differentiate de novo, primarily high-volume metastatic PCa; however, was not able to differentiate between healthy controls, benign prostatic hyperplasia and localized PCa. Similarly, large-scale efforts by the company GRAIL Inc., which developed a ctDNA methylation-based machine learning enabled multi-cancer screening test on more than 6000 plasma samples using 100&#x000a0;000 methylated DNA regions, did not yield favorable PCa screening test statistics in a validation cohort reported on by Klein et al. [<xref ref-type="bibr" rid="CR14">14</xref>]. The authors concluded that this might be due to the inclusion of too many localized PCas, which corroborates the hypothesis that too little ctDNA is shed in early disease stages and therefore alternative analytic approaches, such as proteomics [<xref ref-type="bibr" rid="CR26">26</xref>], might yield more promising biomarkers in this setting in the future. However, a bias toward the investigated meth-ctDNA markers being more specific for CRPC disease cannot be fully excluded.</p><p id="Par37">Advanced CRPC are heterogeneous cancers [<xref ref-type="bibr" rid="CR27">27</xref>] characterized by variable responses to systemic therapies and outcomes. Minimizing therapeutic downtime by identifying progression early is key to maximizing outcomes. However, evidence suggests a frequent disconnection between PSA dynamics and radiographic responses [<xref ref-type="bibr" rid="CR8">8</xref>] or survival outcomes [<xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>], and reliable OS-surrogate intermediate clinical endpoints (ICEs) in mCRPC are missing [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par38">In our CRPC group, both PSA and several meth-ctDNA markers demonstrated similarly strong discriminatory abilities to differentiate between patients with no or any lesion on imaging and non- and metastatic disease presence (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Particularly, <italic>KLF8</italic>, a transcription factor linked to cancer invasion and metastasis [<xref ref-type="bibr" rid="CR31">31</xref>], demonstrated strong discriminatory potential and followed response dynamics in patients undergoing various systemic therapies [<xref ref-type="bibr" rid="CR16">16</xref>]. Analogously, both meth-ctDNA marker PMR and PSA levels were robustly associated with the underlying tumor load in the CRPC group (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>), with PSA exhibiting a slightly stronger correlation with PSMA-TV. Similarly, B&#x000fc;ttner et al. [<xref ref-type="bibr" rid="CR15">15</xref>] investigated the potential of the two ctDNA methylation markers <italic>SHOX2</italic> and <italic>SEPT9</italic> using a methylation-specific PCR approach in a pilot cohort of advanced PCa. They found that both methylation markers correlated with imaging-based tumor burden dynamics under therapy, however, PSA did not consistently follow suit. This corroborates our previous finding that meth-ctDNA markers show potential for detecting and monitoring disease dynamics [<xref ref-type="bibr" rid="CR16">16</xref>], potentially mitigating known challenges of outcome-discordant PSA-based monitoring [<xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. However, as PSA levels were generally at least on par with the meth-ctDNA levels in our CRPC cohort, a possible incremental value of the studied meth-ctDNA markers should be investigated in prospectively collected cohorts with known advanced, low-PSA CRPC.</p><p id="Par39">As CRPC is associated with high mortality [<xref ref-type="bibr" rid="CR2">2</xref>] and OS surrogacy ICEs are needed [<xref ref-type="bibr" rid="CR6">6</xref>], we sought to investigate the comparative predictive value of the investigated meth-ctDNA markers, PSMA-TV and PSA for OS outcomes. Therefore, following an evidence-based variable selection approach, we conducted a multivariate Cox regression analysis (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>), using the median variable values of the overall and CRPC as stratifying cutoffs. <italic>LDAH</italic> (overall cutoff), and expectedly [<xref ref-type="bibr" rid="CR32">32</xref>], PSA levels (CRPC cutoff) were significantly associated with OS and remained independently associated with OS when tested in a comparative fashion, indicating that <italic>LDAH</italic> could be a novel potential ICE for OS surrogacy [<xref ref-type="bibr" rid="CR6">6</xref>] and should be investigated in future trials in the CRPC setting.</p><p id="Par40">Several limitations of our study merit discussion.</p><p id="Par41">First, as a translational clinical study, no novel mechanistic insights into the biological role of the meth-ctDNA markers was generated, which limits mechanistic interpretation. However, several meth-ctDNA markers have been implicated in different hallmark processes of cancer, supporting their biological validity bibliographically. For instance, <italic>AKR1B1</italic>, frequently overexpressed in several cancers, plays diverse roles in cell cycle regulation and epithelial-mesenchymal transition (EMT). Its promoter methylation has also been suggested as a diagnostic marker in breast cancer, and its inhibition has been shown to exhibit anti-neoplastic effects [<xref ref-type="bibr" rid="CR33">33</xref>]. Similarly, <italic>KLF8</italic> has inter alia been implicated in EMT and invasion [<xref ref-type="bibr" rid="CR34">34</xref>] and DNA repair [<xref ref-type="bibr" rid="CR35">35</xref>] in breast cancer. The loss of <italic>LDAH</italic>, a gene coding for a lipid hydrolase, has been linked to an increased risk of PCa in vivo and in vitro [<xref ref-type="bibr" rid="CR36">36</xref>], and altered methylation patterns of clustered protocadherins, including <italic>PCDHGC4</italic>, have been observed in various solid cancers [<xref ref-type="bibr" rid="CR37">37</xref>], while <italic>CHST11</italic> [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>] and <italic>CRABP2</italic> [<xref ref-type="bibr" rid="CR40">40</xref>] have been suggested as potential diagnostic and therapeutic targets due to their involvement in several processes ranging from cancer cell stemness, EMT, cell proliferation, cell cycle and drug resistance in different entities.</p><p id="Par42">Second, the research is limited due to several factors, namely, its small cohort size, monocentricity and retrospective nature, which can all negatively influence generalizability.</p><p id="Par43">The small cohort size could lead to confounding influences and insufficient statistical power, negatively influencing generalizability, particularly in the subgroup analyses.</p><p id="Par44">The mono-centric design did not allow for independent validation of the PSMA-TV correlations with meth-ctDNA, which we tried to mitigate using a multiple-testing correction to avoid false discoveries.</p><p id="Par45">Its retrospective nature, makes us prone to recall and potential selection bias, which we mitigated by excluding patients with inconclusive records and employing an all-comer recruitment strategy. Next, while PSMA PET/CT offers the highest detection for metastatic disease [<xref ref-type="bibr" rid="CR17">17</xref>], false negative lesions can occur, as signified by one patient in our cohort with a PSMA-negative, biopsy-proven pulmonary PCa metastasis. Further, due to the exploratory study design, which aimed at gaining a contextualizing perspective across the whole spectrum of disease, the utilized cohort was biological and therapeutic heterogeneous partially limiting the direct clinical interpretability.</p><p id="Par46">Despite the study's limitations, its strengths also merit acknowledgment. Contemporaneous tracer injection and plasma sampling ensured biological synchronicity for an optimal comparative perspective, and the balanced inclusion of castration statuses allowed for an informative perspective across the disease spectrum.</p><p id="Par47">As the investigated meth-ctDNA markers partially show great potential for accurate, minimally-invasive diagnosis of mCRPC and survival prognostication, their applicability for systemic therapy response prediction, as ICEs for outcome surrogacy and their incremental value for disease monitoring in PSA-low advanced PCa should be investigated in future prospective trials.</p></sec><sec id="Sec14"><title>Conclusion</title><p id="Par48">This study identified ctDNA methylation markers that appear accurate for the minimally-invasive detection and outcome prognostication for advanced, castration-resistant disease but do not seem suitable for clinical characterization of hormone-sensitive PCa. This warrants further prospective studies for their potential applicability for systemic therapy response and outcome prediction in advanced CRPC and their incremental value for disease monitoring in PSA-low advanced PCa.</p></sec><sec id="Sec15" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13148_2025_1811_MOESM1_ESM.pdf"><caption><p>Additional file1 (PDF 2506 KB)</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The Core Facility Genomics and Core Facility Bioinformatics of CEITEC Masaryk University are gratefully acknowledged for the cell-free DNA extraction. The financial support by the Austrian Federal Ministry for Digital and Economic Affairs, the National Foundation for Research, Technology and Development and the Christian Doppler Research Association is gratefully acknowledged. Furthermore, we thankfully acknowledge Siemens Healthineers financial and scientific support.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>The authors confirm their contribution to the paper as follows: K.K., M.H., G.E. helped in study conception and design; K.K., V.L., H.E., D.A. helped in data collection; K.K., V.L., H.E., D.A., D.H., C.S., G.K., B.G., S.S., A.H., M.H., L.K., G.E. helped in analysis and interpretation of results; K.K helped in draft manuscript preparation. All authors reviewed the results and approved the final version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was supported by funds from the Austrian Science Foundation (FWF) (P32771), the Christian Doppler Laboratory for Applied Metabolomics and the Physician-Research Path Scholarship of the Medical University Vienna.</p></notes><notes notes-type="data-availability"><title>Availability of data and material</title><p>Upon request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par49">This study was approved by the ethics committee of the Medical University of Vienna (ID: 1649/2016). All participants signed informed consent for the sample collection, data analysis and result publication. For the retrospective part of the analysis, the need for informed consent was waived by the ethics committee.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par50">Obtained for the prospective part, waived for the retrospective part.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par51">No potential conflicts of interest relevant to this article exist.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><etal/></person-group><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2021</year><volume>71</volume><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209&#x02013;49.<pub-id pub-id-type="pmid">33538338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Howlader N, Noone AM, Krapcho M, Miller D, Brest A. SEER cancer statistics review (CSR), 1975&#x02013;2016. National Cancer Institute. Update April</mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>C</given-names></name><name><surname>Castro</surname><given-names>E</given-names></name><name><surname>Fizazi</surname><given-names>K</given-names></name><name><surname>Heidenreich</surname><given-names>A</given-names></name><name><surname>Ost</surname><given-names>P</given-names></name><name><surname>Procopio</surname><given-names>G</given-names></name><etal/></person-group><article-title>Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up</article-title><source>Ann Oncol</source><year>2020</year><volume>31</volume><fpage>1119</fpage><lpage>1134</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2020.06.011</pub-id><pub-id pub-id-type="pmid">32593798</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1119&#x02013;34.<pub-id pub-id-type="pmid">32593798</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Spring</surname><given-names>DJ</given-names></name><name><surname>Depinho</surname><given-names>RA</given-names></name></person-group><article-title>Genetics and biology of prostate cancer</article-title><source>Genes Dev</source><year>2018</year><volume>32</volume><fpage>1105</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1101/gad.315739.118</pub-id><pub-id pub-id-type="pmid">30181359</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Wang G, Zhao D, Spring DJ, Depinho RA. Genetics and biology of prostate cancer. Genes Dev. 2018;32:1105&#x02013;40.<pub-id pub-id-type="pmid">30181359</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>YA</given-names></name><name><surname>Sfakianos</surname><given-names>J</given-names></name><name><surname>Tewari</surname><given-names>AK</given-names></name><name><surname>Cordon-Cardo</surname><given-names>C</given-names></name><name><surname>Kyprianou</surname><given-names>N</given-names></name></person-group><article-title>Molecular tracing of prostate cancer lethality</article-title><source>Oncogene</source><year>2020</year><volume>39</volume><fpage>7225</fpage><lpage>7238</lpage><pub-id pub-id-type="doi">10.1038/s41388-020-01496-5</pub-id><pub-id pub-id-type="pmid">33046797</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Wang YA, Sfakianos J, Tewari AK, Cordon-Cardo C, Kyprianou N. Molecular tracing of prostate cancer lethality. Oncogene. 2020;39:7225&#x02013;38.<pub-id pub-id-type="pmid">33046797</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Miszczyk</surname><given-names>M</given-names></name><name><surname>Rajwa</surname><given-names>P</given-names></name><name><surname>Fazekas</surname><given-names>T</given-names></name><name><surname>Briganti</surname><given-names>A</given-names></name><name><surname>Karakiewicz</surname><given-names>PI</given-names></name><name><surname>Roupr&#x000ea;t</surname><given-names>M</given-names></name><etal/></person-group><article-title>The state of intermediate clinical endpoints as surrogates for overall survival in prostate cancer in 2024</article-title><source>Eur Urol Oncol</source><year>2024</year><pub-id pub-id-type="doi">10.1016/j.euo.2024.04.004</pub-id><pub-id pub-id-type="pmid">39613565</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Miszczyk M, Rajwa P, Fazekas T, Briganti A, Karakiewicz PI, Roupr&#x000ea;t M, et al. The state of intermediate clinical endpoints as surrogates for overall survival in prostate cancer in 2024. Eur Urol Oncol. 2024. 10.1016/j.euo.2024.04.004.<pub-id pub-id-type="pmid">39613565</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Ilic</surname><given-names>D</given-names></name><name><surname>Djulbegovic</surname><given-names>M</given-names></name><name><surname>Jung</surname><given-names>JH</given-names></name><name><surname>Hwang</surname><given-names>EC</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Cleves</surname><given-names>A</given-names></name><etal/></person-group><article-title>Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis</article-title><source>BMJ</source><year>2018</year><volume>362</volume><fpage>k3519</fpage><pub-id pub-id-type="doi">10.1136/bmj.k3519</pub-id><pub-id pub-id-type="pmid">30185521</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;362:k3519.<pub-id pub-id-type="pmid">30185521</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Bryce</surname><given-names>AH</given-names></name><name><surname>Alumkal</surname><given-names>JJ</given-names></name><name><surname>Armstrong</surname><given-names>A</given-names></name><name><surname>Higano</surname><given-names>CS</given-names></name><name><surname>Iversen</surname><given-names>P</given-names></name><name><surname>Sternberg</surname><given-names>CN</given-names></name><etal/></person-group><article-title>Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL</article-title><source>Prostate Cancer Prostatic Dis</source><year>2017</year><volume>20</volume><fpage>221</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1038/pcan.2016.71</pub-id><pub-id pub-id-type="pmid">28117385</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Bryce AH, Alumkal JJ, Armstrong A, Higano CS, Iversen P, Sternberg CN, et al. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer Prostatic Dis. 2017;20:221&#x02013;7.<pub-id pub-id-type="pmid">28117385</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Casanova-Salas</surname><given-names>I</given-names></name><name><surname>Athie</surname><given-names>A</given-names></name><name><surname>Boutros</surname><given-names>PC</given-names></name><name><surname>Del Re</surname><given-names>M</given-names></name><name><surname>Miyamoto</surname><given-names>DT</given-names></name><name><surname>Pienta</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>Quantitative and qualitative analysis of blood-based liquid biopsies to inform clinical decision-making in prostate cancer</article-title><source>Eur Urol</source><year>2021</year><volume>79</volume><fpage>762</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2020.12.037</pub-id><pub-id pub-id-type="pmid">33422353</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Casanova-Salas I, Athie A, Boutros PC, Del Re M, Miyamoto DT, Pienta KJ, et al. Quantitative and qualitative analysis of blood-based liquid biopsies to inform clinical decision-making in prostate cancer. Eur Urol. 2021;79:762&#x02013;71.<pub-id pub-id-type="pmid">33422353</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>SY</given-names></name><name><surname>Singhania</surname><given-names>R</given-names></name><name><surname>Fehringer</surname><given-names>G</given-names></name><name><surname>Chakravarthy</surname><given-names>A</given-names></name><name><surname>Roehrl</surname><given-names>MHA</given-names></name><name><surname>Chadwick</surname><given-names>D</given-names></name><etal/></person-group><article-title>Sensitive tumour detection and classification using plasma cell-free DNA methylomes</article-title><source>Nature</source><year>2018</year><volume>563</volume><fpage>579</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0703-0</pub-id><pub-id pub-id-type="pmid">30429608</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature. 2018;563:579&#x02013;83.<pub-id pub-id-type="pmid">30429608</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>D</given-names></name><name><surname>Clark</surname><given-names>S</given-names></name><name><surname>Stirzaker</surname><given-names>C</given-names></name><name><surname>Pidsley</surname><given-names>R</given-names></name></person-group><article-title>Advances in prognostic methylation biomarkers for prostate cancer</article-title><source>Cancers</source><year>2020</year><volume>12</volume><fpage>2993</fpage><pub-id pub-id-type="doi">10.3390/cancers12102993</pub-id><pub-id pub-id-type="pmid">33076494</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Lam D, Clark S, Stirzaker C, Pidsley R. Advances in prognostic methylation biomarkers for prostate cancer. Cancers. 2020;12:2993. 10.3390/cancers12102993.<pub-id pub-id-type="pmid">33076494</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Bjerre</surname><given-names>MT</given-names></name><name><surname>N&#x000f8;rgaard</surname><given-names>M</given-names></name><name><surname>Larsen</surname><given-names>OH</given-names></name><name><surname>Jensen</surname><given-names>S&#x000d8;</given-names></name><name><surname>Strand</surname><given-names>SH</given-names></name><name><surname>&#x000d8;stergren</surname><given-names>P</given-names></name><etal/></person-group><article-title>Epigenetic analysis of circulating tumor DNA in localized and metastatic prostate cancer: evaluation of clinical biomarker potential</article-title><source>Cells</source><year>2020</year><volume>9</volume><fpage>1362</fpage><pub-id pub-id-type="doi">10.3390/cells9061362</pub-id><pub-id pub-id-type="pmid">32486483</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Bjerre MT, N&#x000f8;rgaard M, Larsen OH, Jensen S&#x000d8;, Strand SH, &#x000d8;stergren P, et al. Epigenetic analysis of circulating tumor DNA in localized and metastatic prostate cancer: evaluation of clinical biomarker potential. Cells. 2020;9:1362.<pub-id pub-id-type="pmid">32486483</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Petricca</surname><given-names>J</given-names></name><name><surname>Ye</surname><given-names>W</given-names></name><name><surname>Guan</surname><given-names>J</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>N</given-names></name><etal/></person-group><article-title>The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><fpage>6467</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-34012-2</pub-id><pub-id pub-id-type="pmid">36309516</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Chen S, Petricca J, Ye W, Guan J, Zeng Y, Cheng N, et al. The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors. Nat Commun. 2022;13:6467.<pub-id pub-id-type="pmid">36309516</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>EA</given-names></name><name><surname>Richards</surname><given-names>D</given-names></name><name><surname>Cohn</surname><given-names>A</given-names></name><name><surname>Tummala</surname><given-names>M</given-names></name><name><surname>Lapham</surname><given-names>R</given-names></name><name><surname>Cosgrove</surname><given-names>D</given-names></name><etal/></person-group><article-title>Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set</article-title><source>Ann Oncol</source><year>2021</year><volume>32</volume><fpage>1167</fpage><lpage>1177</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2021.05.806</pub-id><pub-id pub-id-type="pmid">34176681</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Klein EA, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32:1167&#x02013;77.<pub-id pub-id-type="pmid">34176681</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000fc;ttner</surname><given-names>T</given-names></name><name><surname>Dietrich</surname><given-names>D</given-names></name><name><surname>Zarbl</surname><given-names>R</given-names></name><name><surname>Kl&#x000fc;mper</surname><given-names>N</given-names></name><name><surname>Ellinger</surname><given-names>J</given-names></name><name><surname>Krausewitz</surname><given-names>P</given-names></name><etal/></person-group><article-title>Feasibility of monitoring response to metastatic prostate cancer treatment with a methylation-based circulating tumor DNA approach</article-title><source>Cancers (Basel)</source><year>2024</year><volume>16</volume><fpage>482</fpage><pub-id pub-id-type="doi">10.3390/cancers16030482</pub-id><pub-id pub-id-type="pmid">38339235</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">B&#x000fc;ttner T, Dietrich D, Zarbl R, Kl&#x000fc;mper N, Ellinger J, Krausewitz P, et al. Feasibility of monitoring response to metastatic prostate cancer treatment with a methylation-based circulating tumor DNA approach. Cancers (Basel). 2024;16:482. 10.3390/cancers16030482.<pub-id pub-id-type="pmid">38339235</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Dillinger</surname><given-names>T</given-names></name><name><surname>Sheibani-Tezerji</surname><given-names>R</given-names></name><name><surname>Pulverer</surname><given-names>W</given-names></name><name><surname>Stelzer</surname><given-names>I</given-names></name><name><surname>Hassler</surname><given-names>MR</given-names></name><name><surname>Scheibelreiter</surname><given-names>J</given-names></name><etal/></person-group><article-title>Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies</article-title><source>Mol Cancer</source><year>2022</year><volume>21</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/s12943-021-01445-0</pub-id><pub-id pub-id-type="pmid">34980142</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Dillinger T, Sheibani-Tezerji R, Pulverer W, Stelzer I, Hassler MR, Scheibelreiter J, et al. Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies. Mol Cancer. 2022;21:7.<pub-id pub-id-type="pmid">34980142</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Perera</surname><given-names>M</given-names></name><name><surname>Papa</surname><given-names>N</given-names></name><name><surname>Roberts</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>M</given-names></name><name><surname>Udovicich</surname><given-names>C</given-names></name><name><surname>Vela</surname><given-names>I</given-names></name><etal/></person-group><article-title>Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis</article-title><source>Eur Urol</source><year>2020</year><volume>77</volume><fpage>403</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2019.01.049</pub-id><pub-id pub-id-type="pmid">30773328</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020;77:403&#x02013;17.<pub-id pub-id-type="pmid">30773328</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Seifert</surname><given-names>R</given-names></name><name><surname>Kessel</surname><given-names>K</given-names></name><name><surname>Schlack</surname><given-names>K</given-names></name><name><surname>Weber</surname><given-names>M</given-names></name><name><surname>Herrmann</surname><given-names>K</given-names></name><name><surname>Spanke</surname><given-names>M</given-names></name><etal/></person-group><article-title>PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2021</year><volume>48</volume><fpage>1200</fpage><lpage>1210</lpage><pub-id pub-id-type="doi">10.1007/s00259-020-05040-1</pub-id><pub-id pub-id-type="pmid">32970216</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Seifert R, Kessel K, Schlack K, Weber M, Herrmann K, Spanke M, et al. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. Eur J Nucl Med Mol Imaging. 2021;48:1200&#x02013;10.<pub-id pub-id-type="pmid">32970216</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Has Simsek</surname><given-names>D</given-names></name><name><surname>Kuyumcu</surname><given-names>S</given-names></name><name><surname>Karadogan</surname><given-names>S</given-names></name><name><surname>Oflas</surname><given-names>M</given-names></name><name><surname>Isik</surname><given-names>EG</given-names></name><name><surname>Ozkan</surname><given-names>ZG</given-names></name><etal/></person-group><article-title>Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?</article-title><source>Ann Nucl Med</source><year>2021</year><volume>35</volume><fpage>680</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1007/s12149-021-01610-x</pub-id><pub-id pub-id-type="pmid">33783752</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Has Simsek D, Kuyumcu S, Karadogan S, Oflas M, Isik EG, Ozkan ZG, et al. Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer? Ann Nucl Med. 2021;35:680&#x02013;90.<pub-id pub-id-type="pmid">33783752</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Kluge</surname><given-names>K</given-names></name><name><surname>Einspieler</surname><given-names>H</given-names></name><name><surname>Haberl</surname><given-names>D</given-names></name><name><surname>Spielvogel</surname><given-names>C</given-names></name><name><surname>Amereller</surname><given-names>D</given-names></name><name><surname>Egger</surname><given-names>G</given-names></name><etal/></person-group><article-title>Comparison of discovery rates and prognostic utility of [68Ga]Ga-PSMA-11 PET/CT and circulating tumor DNA in prostate cancer-a cross-sectional study</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2024</year><volume>51</volume><fpage>2833</fpage><lpage>2842</lpage><pub-id pub-id-type="doi">10.1007/s00259-024-06698-7</pub-id><pub-id pub-id-type="pmid">38693454</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Kluge K, Einspieler H, Haberl D, Spielvogel C, Amereller D, Egger G, et al. Comparison of discovery rates and prognostic utility of [68Ga]Ga-PSMA-11 PET/CT and circulating tumor DNA in prostate cancer-a cross-sectional study. Eur J Nucl Med Mol Imaging. 2024;51:2833&#x02013;42.<pub-id pub-id-type="pmid">38693454</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Beikircher</surname><given-names>G</given-names></name><name><surname>Pulverer</surname><given-names>W</given-names></name><name><surname>Hofner</surname><given-names>M</given-names></name><name><surname>Noehammer</surname><given-names>C</given-names></name><name><surname>Weinhaeusel</surname><given-names>A</given-names></name></person-group><article-title>Multiplexed and sensitive DNA methylation testing using methylation-sensitive restriction enzymes &#x0201c;MSRE-qPCR&#x0201d;</article-title><source>Methods Mol Biol</source><year>2018</year><volume>1708</volume><fpage>407</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-7481-8_21</pub-id><pub-id pub-id-type="pmid">29224156</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Beikircher G, Pulverer W, Hofner M, Noehammer C, Weinhaeusel A. Multiplexed and sensitive DNA methylation testing using methylation-sensitive restriction enzymes &#x0201c;MSRE-qPCR.&#x0201d; Methods Mol Biol. 2018;1708:407&#x02013;24.<pub-id pub-id-type="pmid">29224156</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Seifert</surname><given-names>R</given-names></name><name><surname>Emmett</surname><given-names>L</given-names></name><name><surname>Rowe</surname><given-names>SP</given-names></name><name><surname>Herrmann</surname><given-names>K</given-names></name><name><surname>Hadaschik</surname><given-names>B</given-names></name><name><surname>Calais</surname><given-names>J</given-names></name><etal/></person-group><article-title>Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)</article-title><source>Eur Urol</source><year>2023</year><volume>83</volume><fpage>405</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2023.02.002</pub-id><pub-id pub-id-type="pmid">36935345</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, et al. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol. 2023;83:405&#x02013;12.<pub-id pub-id-type="pmid">36935345</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Eggener</surname><given-names>SE</given-names></name><name><surname>Rumble</surname><given-names>RB</given-names></name><name><surname>Armstrong</surname><given-names>AJ</given-names></name><name><surname>Morgan</surname><given-names>TM</given-names></name><name><surname>Crispino</surname><given-names>T</given-names></name><name><surname>Cornford</surname><given-names>P</given-names></name><etal/></person-group><article-title>Molecular biomarkers in localized prostate cancer: ASCO guideline</article-title><source>J Clin Oncol</source><year>2020</year><volume>38</volume><fpage>1474</fpage><lpage>1494</lpage><pub-id pub-id-type="doi">10.1200/JCO.19.02768</pub-id><pub-id pub-id-type="pmid">31829902</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Eggener SE, Rumble RB, Armstrong AJ, Morgan TM, Crispino T, Cornford P, et al. Molecular biomarkers in localized prostate cancer: ASCO guideline. J Clin Oncol. 2020;38:1474&#x02013;94.<pub-id pub-id-type="pmid">31829902</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Trujillo</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>A</given-names></name><name><surname>Wetterskog</surname><given-names>D</given-names></name><name><surname>Attard</surname><given-names>G</given-names></name></person-group><article-title>Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges</article-title><source>Br J Cancer</source><year>2022</year><volume>127</volume><fpage>1394</fpage><lpage>1402</lpage><pub-id pub-id-type="doi">10.1038/s41416-022-01881-9</pub-id><pub-id pub-id-type="pmid">35715640</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Trujillo B, Wu A, Wetterskog D, Attard G. Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges. Br J Cancer. 2022;127:1394&#x02013;402.<pub-id pub-id-type="pmid">35715640</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Hennigan</surname><given-names>ST</given-names></name><name><surname>Trostel</surname><given-names>SY</given-names></name><name><surname>Terrigino</surname><given-names>NT</given-names></name><name><surname>Voznesensky</surname><given-names>OS</given-names></name><name><surname>Schaefer</surname><given-names>RJ</given-names></name><name><surname>Whitlock</surname><given-names>NC</given-names></name><etal/></person-group><article-title>Low abundance of circulating tumor DNA in localized prostate cancer</article-title><source>JCO Precis Oncol</source><year>2019</year><volume>3</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1200/PO.19.00176</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Hennigan ST, Trostel SY, Terrigino NT, Voznesensky OS, Schaefer RJ, Whitlock NC, et al. Low abundance of circulating tumor DNA in localized prostate cancer. JCO Precis Oncol. 2019;3:1&#x02013;13. 10.1200/PO.19.00176.</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Budnik</surname><given-names>B</given-names></name><name><surname>Amirkhani</surname><given-names>H</given-names></name><name><surname>Forouzanfar</surname><given-names>MH</given-names></name><name><surname>Afshin</surname><given-names>A</given-names></name></person-group><article-title>Novel proteomics-based plasma test for early detection of multiple cancers in the general population</article-title><source>BMJ Oncology</source><year>2024</year><volume>3</volume><fpage>e000073</fpage><pub-id pub-id-type="doi">10.1136/bmjonc-2023-000073</pub-id><pub-id pub-id-type="pmid">39886137</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Budnik B, Amirkhani H, Forouzanfar MH, Afshin A. Novel proteomics-based plasma test for early detection of multiple cancers in the general population. BMJ Oncology. 2024;3:e000073.<pub-id pub-id-type="pmid">39886137</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>R</given-names></name><name><surname>Ryan</surname><given-names>CJ</given-names></name></person-group><article-title>Castration-resistant prostate cancer: targeted therapies and individualized treatment</article-title><source>Oncologist</source><year>2011</year><volume>16</volume><fpage>264</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2010-0216</pub-id><pub-id pub-id-type="pmid">21339259</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Aggarwal R, Ryan CJ. Castration-resistant prostate cancer: targeted therapies and individualized treatment. Oncologist. 2011;16:264&#x02013;75.<pub-id pub-id-type="pmid">21339259</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>C</given-names></name><name><surname>Heinrich</surname><given-names>D</given-names></name><name><surname>O&#x02019;Sullivan</surname><given-names>JM</given-names></name><name><surname>Fossa</surname><given-names>SD</given-names></name><name><surname>Chodacki</surname><given-names>A</given-names></name><name><surname>Demkow</surname><given-names>T</given-names></name><etal/></person-group><article-title>Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases</article-title><source>J Clin Orthod</source><year>2012</year><volume>30</volume><fpage>8</fpage><lpage>8</lpage></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Parker C, Heinrich D, O&#x02019;Sullivan JM, Fossa SD, Chodacki A, Demkow T, et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Orthod. 2012;30:8&#x02013;8.</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>WK</given-names></name><name><surname>Halabi</surname><given-names>S</given-names></name><name><surname>Carducci</surname><given-names>M</given-names></name><name><surname>George</surname><given-names>D</given-names></name><name><surname>Mahoney</surname><given-names>JF</given-names></name><name><surname>Stadler</surname><given-names>WM</given-names></name><etal/></person-group><article-title>Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><fpage>1534</fpage><lpage>1540</lpage><pub-id pub-id-type="doi">10.1200/JCO.2011.39.4767</pub-id><pub-id pub-id-type="pmid">22454414</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30:1534&#x02013;40.<pub-id pub-id-type="pmid">22454414</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Kantoff</surname><given-names>PW</given-names></name><name><surname>Higano</surname><given-names>CS</given-names></name><name><surname>Shore</surname><given-names>ND</given-names></name><name><surname>Berger</surname><given-names>ER</given-names></name><name><surname>Small</surname><given-names>EJ</given-names></name><name><surname>Penson</surname><given-names>DF</given-names></name><etal/></person-group><article-title>Sipuleucel-T immunotherapy for castration-resistant prostate cancer</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><fpage>411</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1001294</pub-id><pub-id pub-id-type="pmid">20818862</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411&#x02013;22.<pub-id pub-id-type="pmid">20818862</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>McKeown-Longo</surname><given-names>PJ</given-names></name><name><surname>Hung</surname><given-names>M-C</given-names></name><etal/></person-group><article-title>Kr&#x000fc;ppel-like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>7184</fpage><lpage>7193</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-4729</pub-id><pub-id pub-id-type="pmid">17671186</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Wang X, Zheng M, Liu G, Xia W, McKeown-Longo PJ, Hung M-C, et al. Kr&#x000fc;ppel-like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion. Cancer Res. 2007;67:7184&#x02013;93.<pub-id pub-id-type="pmid">17671186</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>S</given-names></name><name><surname>Lei</surname><given-names>Z</given-names></name><name><surname>Gong</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Piao</surname><given-names>M</given-names></name></person-group><article-title>Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review</article-title><source>Cancer Cell Int</source><year>2020</year><volume>20</volume><fpage>409</fpage><pub-id pub-id-type="doi">10.1186/s12935-020-01508-0</pub-id><pub-id pub-id-type="pmid">32863768</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Tian S, Lei Z, Gong Z, Sun Z, Xu D, Piao M. Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review. Cancer Cell Int. 2020;20:409.<pub-id pub-id-type="pmid">32863768</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Khayami</surname><given-names>R</given-names></name><name><surname>Hashemi</surname><given-names>SR</given-names></name><name><surname>Kerachian</surname><given-names>MA</given-names></name></person-group><article-title>Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential</article-title><source>J Cell Mol Med</source><year>2020</year><volume>24</volume><fpage>8890</fpage><lpage>8902</lpage><pub-id pub-id-type="doi">10.1111/jcmm.15581</pub-id><pub-id pub-id-type="pmid">32633024</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Khayami R, Hashemi SR, Kerachian MA. Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential. J Cell Mol Med. 2020;24:8890&#x02013;902.<pub-id pub-id-type="pmid">32633024</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>D</given-names></name><name><surname>Hao</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Lahiri</surname><given-names>SK</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name></person-group><article-title>KLF8 promotes invasive outgrowth of breast cancer by inducing filopodium-like protrusions via CXCR4</article-title><source>Am J Transl Res</source><year>2022</year><volume>14</volume><fpage>1220</fpage><lpage>1233</lpage><pub-id pub-id-type="pmid">35273724</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Mukherjee D, Hao J, Lu H, Lahiri SK, Yu L, Zhao J. KLF8 promotes invasive outgrowth of breast cancer by inducing filopodium-like protrusions via CXCR4. Am J Transl Res. 2022;14:1220&#x02013;33.<pub-id pub-id-type="pmid">35273724</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Lahiri</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Wason</surname><given-names>MS</given-names></name><etal/></person-group><article-title>A novel role of Kr&#x000fc;ppel-like factor 8 in DNA repair in breast cancer cells</article-title><source>J Biol Chem</source><year>2012</year><volume>287</volume><fpage>43720</fpage><lpage>43729</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.418053</pub-id><pub-id pub-id-type="pmid">23105099</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Lu H, Hu L, Li T, Lahiri S, Shen C, Wason MS, et al. A novel role of Kr&#x000fc;ppel-like factor 8 in DNA repair in breast cancer cells. J Biol Chem. 2012;287:43720&#x02013;9.<pub-id pub-id-type="pmid">23105099</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Currall</surname><given-names>BB</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Sallari</surname><given-names>RC</given-names></name><name><surname>Cotter</surname><given-names>M</given-names></name><name><surname>Wong</surname><given-names>KE</given-names></name><name><surname>Robertson</surname><given-names>NG</given-names></name><etal/></person-group><article-title>Loss of LDAH associated with prostate cancer and hearing loss</article-title><source>Hum Mol Genet</source><year>2018</year><volume>27</volume><fpage>4194</fpage><lpage>4203</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddy310</pub-id><pub-id pub-id-type="pmid">30169630</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Currall BB, Chen M, Sallari RC, Cotter M, Wong KE, Robertson NG, et al. Loss of LDAH associated with prostate cancer and hearing loss. Hum Mol Genet. 2018;27:4194&#x02013;203.<pub-id pub-id-type="pmid">30169630</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Vega-Benedetti</surname><given-names>AF</given-names></name><name><surname>Loi</surname><given-names>E</given-names></name><name><surname>Moi</surname><given-names>L</given-names></name><name><surname>Blois</surname><given-names>S</given-names></name><name><surname>Fadda</surname><given-names>A</given-names></name><name><surname>Antonelli</surname><given-names>M</given-names></name><etal/></person-group><article-title>Clustered protocadherins methylation alterations in cancer</article-title><source>Clin Epigenetics</source><year>2019</year><volume>11</volume><fpage>100</fpage><pub-id pub-id-type="doi">10.1186/s13148-019-0695-0</pub-id><pub-id pub-id-type="pmid">31288858</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Vega-Benedetti AF, Loi E, Moi L, Blois S, Fadda A, Antonelli M, et al. Clustered protocadherins methylation alterations in cancer. Clin Epigenetics. 2019;11:100.<pub-id pub-id-type="pmid">31288858</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>W-M</given-names></name><name><surname>Li</surname><given-names>L-J</given-names></name><name><surname>Chiu</surname><given-names>I-A</given-names></name><name><surname>Lai</surname><given-names>T-C</given-names></name><name><surname>Chang</surname><given-names>Y-C</given-names></name><name><surname>Tsai</surname><given-names>H-F</given-names></name><etal/></person-group><article-title>The aberrant cancer metabolic gene carbohydrate sulfotransferase 11 promotes non-small cell lung cancer cell metastasis via dysregulation of ceruloplasmin and intracellular iron balance</article-title><source>Transl Oncol</source><year>2022</year><volume>25</volume><fpage>101508</fpage><pub-id pub-id-type="doi">10.1016/j.tranon.2022.101508</pub-id><pub-id pub-id-type="pmid">35985204</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Chang W-M, Li L-J, Chiu I-A, Lai T-C, Chang Y-C, Tsai H-F, et al. The aberrant cancer metabolic gene carbohydrate sulfotransferase 11 promotes non-small cell lung cancer cell metastasis via dysregulation of ceruloplasmin and intracellular iron balance. Transl Oncol. 2022;25:101508.<pub-id pub-id-type="pmid">35985204</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>D-D</given-names></name><name><surname>Li</surname><given-names>J-D</given-names></name><name><surname>He</surname><given-names>R-Q</given-names></name><name><surname>Li</surname><given-names>M-X</given-names></name><name><surname>Pan</surname><given-names>Y-Q</given-names></name><name><surname>He</surname><given-names>X-L</given-names></name><etal/></person-group><article-title>Highly expressed carbohydrate sulfotransferase 11 correlates with unfavorable prognosis and immune evasion of hepatocellular carcinoma</article-title><source>Cancer Med</source><year>2023</year><volume>12</volume><fpage>4938</fpage><lpage>4950</lpage><pub-id pub-id-type="doi">10.1002/cam4.5186</pub-id><pub-id pub-id-type="pmid">36062845</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Xiong D-D, Li J-D, He R-Q, Li M-X, Pan Y-Q, He X-L, et al. Highly expressed carbohydrate sulfotransferase 11 correlates with unfavorable prognosis and immune evasion of hepatocellular carcinoma. Cancer Med. 2023;12:4938&#x02013;50.<pub-id pub-id-type="pmid">36062845</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>Q</given-names></name></person-group><article-title>CRABP2 affects chemotherapy resistance of ovarian cancer by regulating the expression of HIF1&#x003b1;</article-title><source>Cell Death Dis</source><year>2024</year><volume>15</volume><fpage>21</fpage><pub-id pub-id-type="doi">10.1038/s41419-023-06398-4</pub-id><pub-id pub-id-type="pmid">38195606</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Fu X, Zhang Q, Wang Z, Xu Y, Dong Q. CRABP2 affects chemotherapy resistance of ovarian cancer by regulating the expression of HIF1&#x003b1;. Cell Death Dis. 2024;15:21.<pub-id pub-id-type="pmid">38195606</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>